Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - sodium chloride, quantity: 90 mg - injection, solution - excipient ingredients: water for injections - sodium chloride injection solution is used for the restoration and maintenance of salt and extracellular fluid levels or as a vehicle for the administration of parenteral drugs.

Estats Units - anglès - NLM (National Library of Medicine)

hospira, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 900 mg in 100 ml - each of these solutions is indicated for all general irrigation, washing, rinsing and dilution purposes which permit use of a sterile, nonpyrogenic electrolyte solution. not for injection by usual parenteral routes. an electrolyte solution should not be used for irrigation during electrosurgical procedures.

Estats Units - anglès - NLM (National Library of Medicine)

fresenius kabi usa, llc - thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j) - thiamine hydrochloride 100 mg in 1 ml - thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety.  thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe.  it is also indicated when giving iv dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption.  thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually b

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 12 g/l; glutamic acid, quantity: 4.2 g/l; calcium, quantity: 5 mmol/l; lysine hydrochloride, quantity: 8.5 g/l (equivalent: lysine, qty 6.8 g/l); aspartic acid, quantity: 2.5 g/l; tryptophan, quantity: 1.4 g/l; leucine, quantity: 5.9 g/l; potassium, quantity: 50 mmol/l; serine, quantity: 3.4 g/l; sulfate, quantity: 8 mmol/l; acetate, quantity: 135 mmol/l; methionine, quantity: 4.2 g/l; glycine, quantity: 5.9 g/l; cysteine hydrochloride, quantity: 0.61 g/l (equivalent: cysteine, qty 0.42 g - injection, intravenous infusion - excipient ingredients: water for injections - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally.

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius medical care malaysia sdn bhd - sodium chloride (nacl); calcium chloride dihydrate ph. eur.; magnesium chloride hexahydrate pheur; glucose monohydrate, ph eur; sodium lactate solution (50%) -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - adalimumab, quantity: 40 mg - injection, solution - excipient ingredients: mannitol; monobasic sodium phosphate dihydrate; water for injections; sodium chloride; sodium hydroxide; citric acid monohydrate; sodium citrate dihydrate; dibasic sodium phosphate dihydrate; polysorbate 80 - rheumatoid arthritis idacio is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate.,idacio can be used alone or in combination with methotrexate.,juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis idacio in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to one or more disease modifying anti-rheumatic drugs (dmards). idacio can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.,enthesitis-related arthritis idacio is indicated for the treatment of enthesitis-related arthritis in children, who have had an inadequate response to, or who are intolerant to, conventional therapy.,psoriatic arthritis idacio is indicated for the treatment of signs and symptoms, as well as inhibiting the progression of structural damage, of moderate to severely active psoriatic arthritis in adult patients where response to previous dmards has been inadequate.,ankylosing spondylitis idacio is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.,crohn?s disease in adults and children (? 6 years) idacio is indicated for the treatment of moderate to severe crohn?s disease, to reduce the signs and symptoms of the disease and to induce and maintain clinical remission in patients;,? who have had an inadequate response to conventional therapies or, ? who have lost response to or are intolerant to infliximab,ulcerative colitis idacio is indicated for the treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies. patients should show a clinical response within 8 weeks of treatment to continue treatment beyond that time. (see 5.1 pharmacodynamic properties-clinical trials).,psoriasis in adults and children idacio is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.,idacio is indicated for the treatment of severe chronic plaque psoriasis in children and adolescent patients from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.,hidradenitis suppurativa in adults and adolescents (from 12 years of age) idacio is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.,uveitis idacio is indicated for the treatment of non-infectious intermediate, posterior and pan-uveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid sparing, or in whom corticosteroid treatment is inappropriate.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited - sodium pertechnetate(99mtc), quantity: 18.5 gbq - injection, solution - excipient ingredients: water for injections; sodium chloride - technetium [99mtc] generator is used for the preparation of sodium pertechnetate 99m tc injection. sodium pertechnetate 99mtc is used as an agent for: brain imaging, thyroid imaging, salivary gland imaging, blood pool imaging.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - modified liquid gelatine, sodium chloride, magnesium chloride hexahydrate, potassium chloride, sodium lactate solution - solution for infusion - 3 grams - blood substitutes and plasma protein fractions

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty limited - sodium chloride; glucose - anhydrous; glucose (anhydrous) -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty limited - sodium chloride -